Showing results (201-210 of 326) with videos related to
Sort By:
Pageof 33
European Journal of Haematology|January 13, 2026
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data AnalysisNoemi Puig, Xavier Leleu, Hans C Lee, et al.Journal of Athletic Training|April 18, 2024
Exertional Heatstroke Survivors' Knowledge and Beliefs About Exertional Heatstroke Diagnosis, Treatment, and Return to PlayKevin C Miller, Noshir Y Amaria, Douglas J Casa, et al.British Journal of Haematology|March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.Blood Advances|November 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myelomaManisha Bhutani, Myra Robinson, David Foureau, et al.Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.Blood Neoplasia|July 12, 2026
CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlatesNezar Mehanna, Andriy Derkach, Billel Gasmi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.Blood Advances|December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXAndrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 12, 2018
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of ActionHomer C Adams, Frederik Stevenaert, Jakub Krejcik, et al.Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.Pageof 33